Biosimilars: ensuring safety in the search for savings

Biosimilars – cheaper versions of biopharmaceuticals produced by competing companies – have the potential to reduce the NHS drugs bill substantially. However, unlike generic drugs, biosimilars are not interchangeable with the original brand, raising safety concerns. Hence pharmacovigilance and prescribing by brand is essential.

Source: Prescriber - May 2, 2017 Category: Primary Care Authors: Mark Greener Tags: Drug Development Source Type: research